Imagine a world where patients with chronic lymphocytic leukemia (CLL) could achieve the same survival rates without being tied to endless treatment cycles. This groundbreaking study challenges the status quo, revealing that fixed-duration therapy might be just as effective as continuous treatment. But here's where it gets controversial: could this shift the paradigm of CLL treatment, potentially sparing patients from lifelong medication? Let’s dive into the details.
A recent phase 3 study presented at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, has turned heads in the oncology community. The research, stemming from the multicenter, randomized, open-label CLL17 clinical trial (NCT04608318), compared fixed-duration venetoclax-based therapies with continuous ibrutinib in previously untreated CLL patients. The results? Fixed-duration treatments, specifically venetoclax combined with obinutuzumab (VO) or ibrutinib (VI), demonstrated progression-free survival (PFS) rates on par with continuous ibrutinib (Imbruvica).
Lead author Othman Al-Sawaf, MD, from the University Hospital of Cologne in Germany, emphasized during an ASH news conference, “Most patients with untreated CLL should now be considered for fixed-duration treatments to allow for treatment-free intervals, though longer follow-up will further validate our findings, especially regarding subgroups and long-term survival implications.”
The study enrolled 909 patients, randomly assigned in a 1:1:1 ratio to receive VO, VI, or continuous ibrutinib. Patients were stratified based on immunoglobulin heavy chain variable (IGHV) mutation status, del17p/TP53 mutation, and overall fitness. As of the data cutoff on April 11, 2025, the median observation time was 34.2 months, with participants averaging 66 years of age. Notably, 56.5% had unmutated IGHV, 19.2% had complex karyotypes, and 7.6% carried del(17p) or TP53 mutations.
Dr. Al-Sawaf highlighted that nearly half of the patients were deemed ‘unfit’ due to coexisting conditions, a subgroup often overlooked in clinical trials. “These patients have a lot of coexisting conditions in addition to CLL, making their treatment particularly challenging,” he noted.
At the three-year mark, PFS rates were strikingly similar: 81.1% for VO and 81.0% for ibrutinib (hazard ratio [HR], 0.87; adjusted 98.3% CI, 0.54–1.41). The VI group closely followed with a 79.4% PFS rate (HR, 0.84; adjusted 98.0% CI, 0.53–1.32). Both comparisons met the prespecified noninferiority threshold, indicating that fixed-duration treatments hold their ground against continuous therapy.
Objective response rates at cycle 18 day 1 were impressive across the board: 84.2% for VO, 88.5% for VI, and 86.0% for ibrutinib. Complete response rates, however, varied significantly, with VO at 51.5%, VI at 46.2%, and ibrutinib at a mere 8.3%. Undetectable measurable residual disease in peripheral blood was achieved in 73.3% of VO patients, 47.2% of VI patients, and none in the ibrutinib group.
Overall survival at three years was also promising: 91.5% for VO, 96.0% for VI, and 95.7% for ibrutinib. Subgroup analyses revealed consistent PFS patterns across IGHV and TP53 subgroups, though high-risk populations showed smaller numbers.
Adverse events were prevalent across all groups, with infections, gastrointestinal issues, and hematologic toxicities leading the list. Cardiac disorders were more frequent in the ibrutinib group (34.6%) compared to VO (13.9%) and VI (23.8%), raising questions about the long-term safety of continuous treatment.
Laura Michaelis, MD, of the Medical College of Wisconsin, commented on the study’s significance: “One of the biggest challenges in treating CLL is balancing symptom relief with treatment duration. CLL17 provides crucial insights into the risks and benefits of fixed-duration versus continuous therapies.”
This study stands out as one of the largest head-to-head comparisons of CLL treatments, offering clinicians and patients valuable data to make informed decisions. Dr. Michaelis added, “The noninferiority of fixed-duration treatments suggests that patients can achieve equivalent survival outcomes without indefinite therapy. I’m particularly interested in the outcomes for TP53-mutated patients, as this subgroup often faces poorer prognoses.”
But here’s the controversial part: If fixed-duration treatments prove equally effective, should continuous therapies like ibrutinib still be the default choice? Could we be overtreating patients, exposing them to unnecessary risks and side effects? We’d love to hear your thoughts in the comments below.
Additional reporting for this story provided by Leah Lawrence.
Disclosures: Dr. Al-Sawaf reported research funding and consulting relationships with AbbVie, Janssen, Roche, BeiGene, Genmab, Eli Lilly, and AstraZeneca. Dr. Michaelis reported no relevant conflicts of interest.
© 2025 HealthCentral LLC. All rights reserved.
